Treatment of gestational diabetes

Details Treatment of gestational diabetes Treatment of gestational diabetes

2005-11-17

2008-11-18

Schultz, J D (Department: 1639)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S003100, C514S004300, C514S012200, C530S300000, C530S324000, C530S325000

Reexamination Certificate

active

07452858

ABSTRACT:
Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.

REFERENCES:
patent: 5424286 (1995-06-01), Eng
patent: 5602133 (1997-02-01), Antonucci et al.
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5686511 (1997-11-01), Bobo
patent: 6136784 (2000-10-01), L'Italien et al.
patent: 6506724 (2003-01-01), Hiles et al.
patent: 6872700 (2005-03-01), Young et al.
patent: 6989366 (2006-01-01), Beeley et al.
patent: 7115569 (2006-10-01), Beeley et al.
patent: 7138375 (2006-11-01), Beeley et al.
patent: 7153825 (2006-12-01), Young et al.
patent: 7223725 (2007-05-01), Beeley et al.
patent: 2004/0266670 (2004-12-01), Hiles et al.
patent: 2006/0148713 (2006-07-01), Beeley et al.
patent: 98/05351 (1998-02-01), None
patent: 98/30231 (1998-07-01), None
patent: 99/07404 (1999-02-01), None
patent: 99/25728 (1999-05-01), None
patent: 99/40788 (1999-08-01), None
patent: 00/41548 (2000-07-01), None
patent: 00/66629 (2000-11-01), None
Csorba et al., Critical Reviews in Clinical Laboratory Sciences. vol. 3(5) 509-550; 1995.
American Diabetes Association, “Self-Monitoring of Blood Glucose”,Diabetes Care, vol. 17, No. 1, pp. 81-82 (1994).
American Diabetes Association, “Gestational Diabetes Mellitus”,Diabetes Care, vol. 21, Supplemental 1, pp. S60-S61 (1998).
Applied Biosystems, “Introduction to Cleavage Techniques”,Strategies in Peptide Synthesis, pp. 6-12 (1990).
Bartlett and Lamden, “Inhibition of Chymotrypsin by Phosphonate and Phosphonamidate Peptide Analogs”Bioorganic Chemistry, vol. 14, pp. 356-377 (1986).
Bhavsar et al, “Inhibition of Gastric Emptying and of Food Intake Appear to be Independently Controlled in Rodents”,Soc. Neurosci. Abstracts, vol. 21, Abstract No. 188.8 (1995).
Carr, “Screening for Gestational Diabetes Mellitus”,Diabetes Care, vol. 21, Supplemental 21, pp. B14-B18 (1998).
Coetzee et al, “Diabetes newly diagnosed during pregnancy”,S. Afr. Med. J., vol. 56, pp. 467-475 (1979).
Coustan, “Gestational Diabetes”,Diabetes in America, 2ndEd. National Institutes of Health, Publication No. 95-1468(1995).
D'Alessio et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons”,The Journal of Clinical Investigation, vol. 97, No. 1, pp. 133-138(1996).
Eissele et al, “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagonlike Peptide-1 (GLP-1) Amide”,Life Sciences, vol. 55, No. 8, pp. 629-634 (1994).
Eng et al, “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom”,The Journal of Biological Chemistry, vol. 265, No. 33, pp. 20259-20262 (1990).
Eng et al, “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom”,The Journal of Biological Chemistry, vol. 267, No. 11, pp. 7402-7405 (1992).
Fehmann et al, “Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39)”,Peptides, vol. 15, No. 3, pp. 453-456 (1994).
Goke et al, “Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1 -(7-36)-amide Receptor of Insulin-secreting p-Cells”,The Journal of Biological Chemistry, vol. 268, No. 26, pp. 19650-19655 (1993).
Greig et al, “Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations”,Diabetologia, vol. 42, pp. 45-50 (1999).
Jovanovic, “American Diabetes Association's Fourth International Workshop-Conference on Gestational Diabetes Mellitus: Summary and Discussion”,Diabetes Care, vol. 21, Supplement 2, pp. B131-B137 (1998).
Jovanovic-Petersen et al, “Dietary Manipulation as a Primary Treatment Strategy for Pregnancies Complicated by Diabetes”,Journal of the American College of Nutrition, vol. 9, No. 4, pp. 320-325 (1990).
Kahn et al, “Insulin, Oral Hypoglycemic Agents, and the Pharmacology of the Endocrine Pancreas”,Insulin, Chapter 61, pp. 1463-1495.
Kolligs et al, “Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9-39) Amide”,Diabetes, vol. 44, pp. 16-19 (1995).
“Etiology and Pathogenesis of Gestational Diabetes”,Diabetes Care, vol. 21, Supplement 2, pp. B19-B26 (1998), Kuhl.
Langer and Mazze, “The relationship between large-for-gestational-age infants and glycemic control in women with gestational diabetes”,Am. J. Obstet. Gynecol, vol. 159, No. 6, pp. 1478-1483 (1998).
Langer et al, “Glycemic control in Gestational diabetes mellitus—How tight is tight enough: Small for gestational age versus large for gestational age?”,Am. J. Obstet. Gynecol, vol. 161, No. 3, pp. 646-653 (1989).
Langer et al, “Gestational Diabetes is a Clinical Entity: The Price of Not Treating”,American Journal of Obstetrics and Gynecology, vol. 176, No. 1, p. S182, Abstract No. 640 (1997).
Langer, “Maternal Glycemic Criteria for Insulin Therapy in Gestational Diabetes Mellitus”,Diabetes Care, vol. 21, Supplement 2, pp. B91-B98 (1998).
Malhotra et al, “Exendin-4, a new peptide fromHeloderma suspectumvenom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini”,Regulatory Peptides, vol. 41, pp. 149-156 (1992).
Metzger, “1990 Overview of GDM, Accomplishments of the Last Decade—Challenges for the Future”,Diabetes, vol. 40, Supplement 2, pp. 1-2 (1991).
Molecular Cloning, Second Edition (Table of Contents), pp. v-xxix (1989), Sambrook et al.
Montrose-Rafizadeh et al, “Structure-function Analysis of Exendin-4/GLP-1 Analogs”,Diabetes, vol. 45, Supplement 2, p. 152A, Abstract No. 553 (1995).
O'Halloran et al, “Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man”,Journal of Endocrinology, vol. 126, pp. 169-173 (1990).
Orskov et al, “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects are Indistinguishable”,Diabetes, vol. 42, pp. 658-661 (1993).
Persson et al, “Diabetes Mellitus and Pregnancy”,International Textbook of Diabetes Mellitus, Second Edition, Chapter 57, pp. 1135-1149 (1997).
Raufman et al, “Exendin-3, a Novel Peptide fromHeloderma horridumVenom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas”,The Journal of Biological Chemistry, vol. 256, No. 5, pp. 2897-2902 (1991).
Raufman et al, “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors Dispersed Acini from Guinea Pig Pancreas”,The Journal of Biological Chemistry, vol. 267, No. 30, pp. 21432-21437 (1992).
Roversi et al, “Maximal Tolerated Insulin Therapy in Gestational Diabetes”,Diabetes Care, vol. 3, No. 3, pp. 489-494 (1980).
Schepp et al, “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rate parietal cell receptor for glucagon-like peptide-1-(7-36)NH2”,European Journal of Pharmacology—Molecular Pharmacology Section 269, pp. 183-191 (1994).
Schjoldager et al, “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans”,Digestive Diseases and Sciences, vol. 34, No. 5, pp. 703-708 (1989).
Sermer et al, “The Toronto Tri-Hospital Gestational Diabetes Project”,Diabetes Care, vol. 21, Supplement 2, pp. B33-B42 (1998).
Siccardi, “Gestational Diabetes”, The

Affiliated with

Also associated with

Rating

Treatment of gestational diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of gestational diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of gestational diabetes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4040963